目的：观察病理性近视(pathologic myopia，PM)黄斑脉络膜新生血管(choroidal neovascularization，CNV)经Avastin治疗后眼部病变和最佳矫正视力(best corrected visual acuity，BCVA)变化，结合光相干断层扫描(optical coherence tomography，OCT)，荧光素眼底血管造影(fluorescence fundus angiography，FFA)的结果，评价Avastin治疗PM黄斑CNV的临床疗效和安全性。

方法：PM黄斑CNV 41例42眼，随机分为两组，试验组21例22眼采用玻璃体腔注射Avastin联合口服复方血栓通胶囊治疗； 对照组20例20眼仅口服复方血栓通胶囊治疗，剂量、疗程同实验组。两组随访时间均为12mo，统计分析两组BCVA、眼底检查、FFA及OCT检查结果，评价Avastin治疗PM黄斑CNV的临床疗效和安全性。

结果：BVCA：试验组平均提高4.23±2.02行，对照组平均提高1.95±1.90行，组间差异有统计学意义(P<0.005)，试验组提高较对照组明显； OCT：比较两组中央视网膜厚度(central foveal thickness，CFT)，试验组和对照组减低平均值分别是43.41±40.39和22.65±20.79μm，组间差异有统计学意义(P<0.05)，实验组CFT减低程度较对照组明显； FFA：治疗后试验组20眼(91%)渗漏消失，2眼(9%)渗漏持续存在； 对照组12眼(60%)完全消失，8眼(40%)持续存在，组间差异有统计学意义(P<0.05)，实验组渗漏明显减轻。

结论：Avastin可有效减轻病理性近视CNV的渗漏，缩短病程，提高视力，治疗安全。

AIM: To evaluate the efficacy and safety of intravitreal bevacizumab(Avastin)for choroidal neovascularization(CNV)in pathologic myopia(PM)by including optical coherence tomography(OCT), fluorescein angiography(FFA)and best-corrected visual acuity(BCVA).

METHODS: Totally 42 eyes in 41 patients with PM CNV were divided into 2 groups randomly, experimental group(n=22)were assigned to receive intravitreal bevacizumab injections and take fufangxueshuantong capsule; control group(n=20)just took fufangxueshuantong capsule. Subjects were followed up every month after treatment. The efficacy and safety of two group were compared by ophthalmic evaluations including OCT, FFA, and BCVA.

RESULTS: BCVA: BCVA in two groups was improved after 12 months. The mean number of treatments per eye, experimental group was 4.23±2.02 and control group was 1.95±1.90. There was significant difference(P<0.005). OCT: Before and after 12 months central foveal thickness(CFD)for two groups were thin,and the mean value in experimental group was 43.41±40.39μm and in control group was 22.65±20.79μm, there was significant difference(P<0.05); FFA: In experimental group CNV was completely disappeared in 20 eyes(91%), persistent in 2 eyes(9%); the control group CNV was completely disappeared in 12 eyes(60%), persistent in 8 eyes(40%). There was significant difference(P<0.05).

CONCLUSION: Intravitreal bevacizumab are safe and effective treatment for most patients of CNV in PM.